Thu, October 1, 2009
Wed, September 30, 2009
Tue, September 29, 2009
Mon, September 28, 2009
Fri, September 25, 2009
Thu, September 24, 2009
Wed, September 23, 2009
Tue, September 22, 2009
Mon, September 21, 2009
Fri, September 18, 2009
Thu, September 17, 2009
Wed, September 16, 2009
Tue, September 15, 2009
Mon, September 14, 2009
Fri, September 11, 2009
Thu, September 10, 2009
Wed, September 9, 2009
Tue, September 8, 2009
Sun, September 6, 2009
Fri, September 4, 2009
Thu, September 3, 2009
Wed, September 2, 2009
Tue, September 1, 2009
Mon, August 31, 2009
Fri, August 28, 2009
Thu, August 27, 2009
Wed, August 26, 2009
Tue, August 25, 2009
Mon, August 24, 2009
Sun, August 23, 2009
Fri, August 21, 2009
Thu, August 20, 2009
Wed, August 19, 2009
Tue, August 18, 2009
Mon, August 17, 2009
Sun, August 16, 2009
Fri, August 14, 2009
Thu, August 13, 2009
Wed, August 12, 2009
Tue, August 11, 2009
Mon, August 10, 2009
Fri, August 7, 2009

SciClone Pharmaceuticals, Inc.: SciClone Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference


//health-fitness.news-articles.net/content/2009/ .. renshaw-annual-global-investment-conference.html
Published in Health and Fitness on Friday, September 4th 2009 at 13:13 GMT by Market Wire   Print publication without navigation


FOSTER CITY, CA--(Marketwire - September 4, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: [ SCLN ]) today announced that it will present at the Rodman & Renshaw Annual Global Investment Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business update on Thursday, September 10, 2009 at 10:50 am ET.

To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at [ www.sciclone.com ].

About SciClone

SciClone Pharmaceuticals (NASDAQ: [ SCLN ]) is a profit-driven, global biopharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and expense management. ZADAXIN (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; RP101 in a phase 2 trial for the treatment of pancreatic cancer; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 with a ready-to-initiate phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead™ in China, where the product is under regulatory review. The Company also has commercialization and distribution rights to an anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which it is seeking regulatory approval. For additional information, please visit [ www.sciclone.com ].


Publication Contributing Sources

Similar Health and Fitness Publications